Charité Campus Benjamin Franklin

Running trials

• Active, not recruiting

  WATCHMAN FLX Pro European Registry

  NCT07262255· Source

• Recruiting

  BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation

  NCT05717192· Source

• Recruiting

  A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

  NCT06150157· Phase 1· Source

• Active, not recruiting

  A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

  NCT05993234· Source

• Recruiting

  German Dementia Registry

  NCT07433010· Source

• Active, not recruiting

  CHAMPION-AF Clinical Trial

  NCT04394546· Source

• Active, not recruiting

  Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

  NCT03767348· Phase 2· Source

• Recruiting

  Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis

  NCT03256240· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Myeloproliferative neoplasms1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

  NCT05560646· Phase 2· Source

• Completed

  Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization

  NCT04931771· Source

• Completed

  Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab

  NCT03480438· Phase 2· Source

• Completed

  Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

  NCT03070392· Phase 2· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Source